| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
In this study, anti-paclitaxel (PAC) scFv was successfully prepared and combined with anti-Her2 or LAT1 scFv. The yield of the bispecific scFv was sufficientwith an expression system using Escherichia coli.. The expressed bispecific scFv was purified and evaluated contribution of anti-cancer property. On in vitro assay, we treated some cancer cells with PAC and the bispecific scFv. However, there is no significant difference between this experimental condition and the control regarding anti-cancer activity. We will verify the refolding system of the bispecific antibody to give more stable activity, and in addition, we will modify structure of recombinant antibodies for application of a drug delivery system.
|
